Alzheimer's drug candidate NH280105 passes first safety check in healthy adults
NCT ID NCT06870058
First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 26 times
Summary
This early-phase study tested a new drug called NH280105 in 32 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects and changes in lab results. This is a first step toward possibly treating Alzheimer's disease, but much more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia
Conditions
Explore the condition pages connected to this study.